For example, Cobas EGFR mutation test v2 using plasma EGFR genetic testing for monitoring of disease progression of NSCLC received the FDA approval in 2016 to identify the mutation of exon 19 deletions and exon 21 substitutions throughout the time of fewer than 4 h. Here, EGFR is linked to non-small cell lung carcinoma.